Serum antibodies to microbial antigens for Crohn’s disease progression

Xiong, Yao; Wang, Gou-Zhen; Zhou, Jieqiong; Xia, Bingqing; Wang, Xinying; Jiang, Bo

doi:10.1097/meg.0000000000000102

Cited by 30 publications

(16 citation statements)

References 58 publications

(128 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis evaluated the stratification powers of ASCA, antibodies to OmpC, Cbir1 and I2 in characterizing progression of Crohn’s disease (CD). Anti-OmpC was associated with the highest risk of both complications and surgery in CD patients, and the power became stronger when antibodies were assessed in combination 103 .…”

Section: Prognosismentioning

confidence: 97%

Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases

Dubinsky

Braun

2015

Gastroenterology

View full text Add to dashboard Cite

The microbiome plays multi-faceted roles in the pathogenesis of inflammatory bowel diseases (IBD). Accordingly, the clinical challenge of patient heterogeneity in disease phenotype and response to treatment should in part be addressed by biomarkers that detect the host response to microbiota, and the levels of microbial taxa and products eliciting the host response in susceptible individuals. Molecular analysis has revealed much evidence for microbial taxonomic membership and microbial products in association with IBD, but their utility as clinical biomarkers is still in its infancy. A rich area of progress has been the development and validation of host serologic microbial biomarkers, which have achieved a distinctive position in the diagnosis and prognosis in IBD, and as a template for defining other categories of microbial biomarkers in disease state and phenotype.

show abstract

Section: Prognosismentioning

confidence: 97%

Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases

Dubinsky

Braun

2015

Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Since S. cerevisiae antibodies have been documented in patients with Celiac [9] or Crohn's disease [10], he was evaluated by gastroenterology. In September 2016, he had an upper endoscopy and colonoscopy.…”

Section: Case Reportmentioning

confidence: 99%

A Case of Chronic Cough in a Winemaker

Viteri

Foray

Song

et al. 2017

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

BackgroundFungi have been known to cause a variety of respiratory conditions, ranging from mold- associated asthma to allergic bronchopulmonary mycosis and invasive disease. More recently some fungal species have been implicated in a non-asthmatic chronic cough syndrome.Case presentationA 59-year-old male presented to the pulmonary clinic with chronic nonproductive cough. Workup included pulmonary function tests with methacholine challenge, sputum cultures, CT scans of the chest and therapeutic trial with proton pump inhibitors. Sputum cultures repeatedly showed Saccharomyces cerevisiae and patient had elevated specific IgA and IgG. Bronchoscopy was unremarkable, except for tracheal mucosa biopsies revealing acute and chronic inflammation. A one-month course of steroids provided temporary relief of chronic cough, but symptoms returned once steroids were discontinued. He also experienced temporary relief away from home. Upon further evaluation, the patient described his hobby of wine making which was believed to be the source of Saccharomyces cerevisiae. Once he stopped wine making at home and cleared his cellar, his symptoms stopped and have not returned since.ConclusionWe describe a rare presentation of non-asthmatic chronic cough associated with exposure to Saccharomyces cerevisiae. This is the first report of fungi associated chronic cough without asthmatic features outside of Japan and the first one associated with Saccharomyces cerevisiae. This report provides further evidence linking fungi with chronic cough syndrome without the features of asthma or allergic bronchopulmonary mycosis.

show abstract

“…48 A recent meta-analysis on 11 studies and based on four antibodies -ASCA, anti-OmpC, anti-I2 and antiCBir1 -identified ASCA as the antibody with the highest sensitivity and anti-OmpC as that with the highest specificity for complications and surgery. 49 Moreover, disease progression towards complications was predicted more effectively using at least two antimicrobial antibodies rather than any single one. 49 All the antimicrobial antibodies are useful for predicting a disabling course of Crohn's disease (Table 1), but not for discriminating between stricturing and nonstricturing phenotypes.…”

Section: Antimicrobial Antibodiesmentioning

confidence: 99%

“…49 Moreover, disease progression towards complications was predicted more effectively using at least two antimicrobial antibodies rather than any single one. 49 All the antimicrobial antibodies are useful for predicting a disabling course of Crohn's disease (Table 1), but not for discriminating between stricturing and nonstricturing phenotypes. Further prospective studies are needed to ascertain whether circulating antibodies, alone or in conjunction with other biomarkers, can predict the disease course and the development of fibrosis in IBD.…”

Section: Antimicrobial Antibodiesmentioning

confidence: 99%

Biomarkers of intestinal fibrosis – one step towards clinical trials for stricturing inflammatory bowel disease

Giuffrida

Pinzani

Corazza

et al. 2016

United European Gastroenterology Journal

View full text Add to dashboard Cite

Intestinal fibrosis, caused by an excessive deposition of extracellular matrix components, and subsequent stricture development are a common complication of inflammatory bowel disease. However, currently there are no biomarkers which reliably predict the risk of developing intestinal strictures or identify early stages of fibrosis prior to clinical symptoms. Candidate biomarkers of intestinal fibrosis, including gene variants (i.e. nucleotide-binding oligomerization domain-2 gene), serum microRNAs (miR-19, miR-29), serum extracellular matrix proteins (i.e. collagen, fibronectin) or enzymes (i.e. tissue inhibitor of matrix metalloproteinase-1), serum growth factors (i.e. basic fibroblast growth factor, YKL-40), serum anti-microbial antibodies (i.e. anti-Saccharomyces cerevisiae) and circulating cells (i.e. fibrocytes) have shown conflicting results on relatively heterogeneous patients' cohorts, and none of them was proven to be strictly specific for fibrostenosis, but rather predictive of a disease disabling course. In this review we critically reassess the diagnostic and prognostic value of serum biomarkers of intestinal fibrosis in inflammatory bowel disease.

show abstract

Serum antibodies to microbial antigens for Crohn’s disease progression

Abstract: Anti-OmpC had the highest stratification power among the four antibodies screened for the risk of both complications and surgery in CD patients, and the power became stronger when antibodies were assessed in combination.

Cited by 30 publications

References 58 publications

Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases

Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases

A Case of Chronic Cough in a Winemaker

Biomarkers of intestinal fibrosis – one step towards clinical trials for stricturing inflammatory bowel disease

Contact Info

Product

Resources

About